MAPT and early-onset autosomal dominant Alzheimer disease: Although moscatilin possesses the ability to facilitate tau phosphorylation in an in vitro Alzheimer’s disease-like model developed by cotransfection with the amyloid precursor protein and tau-related plasmids, or is induced by okadaic acid, it cannot evaluate the effect of moscatilin on the mitigation of glycation mediated damages in neuronal cells [37].